天美传媒

Abstract

Paediatric neurogenic bladder is a complex condition resulting from disrupted communication between the brain and the bladder, often caused by neurological disorders such as spina bifida, cerebral palsy, and spinal cord injuries. When conventional treatments prove inadequate, intravesical botulinum toxin type A pharmacotherapy has emerged as a promising intervention. This article explores the mechanism, benefits, considerations, and potential future directions of intravesical BoNT-A pharmacotherapy for paediatric neurogenic bladder. By temporarily relaxing overactive bladder muscles, BoNT-A injections offer symptomatic relief, improved bladder function, and the potential to prevent complications. As ongoing research refines administration techniques and dosages, intravesical BoNT-A pharmacotherapy may play an increasingly important role in enhancing the quality of life for paediatric patients with neurogenic bladder.